MLYS insider transaction filings
Mineralys Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-12. Screen MLYS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-12 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 2,170 @ $16 · Sale (S): 2,170 @ $27.09 · Option exercise (M): 2,170 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Ferguson James J. III — Chief Medical Officer | Grant/award (A): 102,400 @ $0 · Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2026-07-23 | 4 | Warren Eric — Chief Commercial Officer | Option exercise (M): 7,438 @ $13.24 · Sale (S): 7,438 @ $26.87 · Option exercise (M): 7,438 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 416 @ $15.44 · Sale (S): 416 @ $26.53 · Option exercise (M): 416 (derivative) @ $0 | EDGAR |
| 2026-07-15 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 3,542 @ $10.20 · Option exercise (M): 4,167 @ $14.25 · Option exercise (M): 6,349 @ $1.08 · Sale (S): 14,058 @ $27.58 · Sale (S): 6,349 @ $26.61 · Option exercise (M): 3,542 (derivative) @ $0 · +2 more | EDGAR |
| 2026-07-15 | 4 | Congleton Jon — Chief Executive Officer, Director | Sale (S): 10,700 @ $27.24 | EDGAR |
| 2026-07-10 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 2,171 @ $16 · Sale (S): 2,171 @ $30.30 · Option exercise (M): 2,171 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Warren Eric — Chief Commercial Officer | Option exercise (M): 104,124 @ $13.24 · Sale (S): 104,124 @ $25.90 · Option exercise (M): 104,124 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Congleton Jon — Chief Executive Officer, Director | Sale (S): 58,000 @ $25.94 · Sale (S): 17,000 @ $26.82 | EDGAR |
| 2026-06-17 | 4 | Karydas Daphne — Director | Option exercise (M): 3,000 @ $12.02 · Sale (S): 3,000 @ $25 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 3,542 @ $10.20 · Sale (S): 9,890 @ $23.81 · Option exercise (M): 4,167 @ $14.25 · Option exercise (M): 417 @ $15.44 · Sale (S): 4,584 @ $25 · Option exercise (M): 3,542 (derivative) @ $0 · +2 more | EDGAR |
| 2026-06-12 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 2,170 @ $16 · Sale (S): 2,170 @ $25 · Option exercise (M): 6,349 @ $1.08 · Sale (S): 6,349 @ $23.93 · Option exercise (M): 2,170 (derivative) @ $0 · Option exercise (M): 6,349 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 417 @ $15.44 · Sale (S): 417 @ $27.55 · Option exercise (M): 417 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 2,171 @ $16 · Sale (S): 2,171 @ $29.71 · Option exercise (M): 6,348 @ $1.08 · Sale (S): 6,348 @ $29.36 · Option exercise (M): 3,541 @ $10.20 · Option exercise (M): 4,166 @ $14.25 · +5 more | EDGAR |
| 2026-04-21 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 416 @ $15.44 · Sale (S): 416 @ $31.33 · Option exercise (M): 416 (derivative) @ $0 | EDGAR |
| 2026-04-15 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 6,349 @ $1.08 · Option exercise (M): 3,542 @ $10.20 · Option exercise (M): 4,167 @ $14.25 · Sale (S): 14,058 @ $26.54 · Sale (S): 6,348 @ $27.66 · Option exercise (M): 6,349 (derivative) @ $0 · +2 more | EDGAR |
| 2026-04-15 | 4 | Congleton Jon — Chief Executive Officer, Director | Sale (S): 15,730 @ $26.83 | EDGAR |
| 2026-04-13 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 2,170 @ $16 · Sale (S): 2,170 @ $27.38 · Option exercise (M): 2,170 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Karydas Daphne — Director | Option exercise (M): 3,000 @ $12.02 · Sale (S): 3,000 @ $25 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Congleton Jon — Chief Executive Officer, Director | Sale (S): 19,364 @ $25.50 · Sale (S): 55,183 @ $26.54 · Sale (S): 453 @ $27.05 | EDGAR |
| 2026-03-31 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director RA Capital Healthcare Fund LP — Director RA Capital Nexus Fund III, L.P. — Director Kolchinsky Peter — Director Shah Rajeev M. — Director | Purchase (P): 310,700 @ $23.67 · Purchase (P): 58,300 @ $24.16 | EDGAR |
| 2026-03-17 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 417 @ $15.44 · Sale (S): 417 @ $25.65 · Option exercise (M): 417 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 6,348 @ $1.08 · Sale (S): 6,348 @ $27.37 · Option exercise (M): 3,542 @ $10.20 · Option exercise (M): 4,167 @ $14.25 · Sale (S): 10,726 @ $25.91 · Sale (S): 3,079 @ $27.37 · +4 more | EDGAR |
| 2026-03-10 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 2,171 @ $16 · Sale (S): 2,171 @ $26.84 · Option exercise (M): 2,171 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Gold Alexander M — Director | Grant/award (A): 6,200 @ $0 · Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Slingsby Brian Taylor — Director, 10% owner | Grant/award (A): 6,200 @ $0 · Other (J): 6,200 @ $0 · Other (J): 6,200 @ $0 · Grant/award (A): 8,300 (derivative) @ $0 · Other (J): 8,300 (derivative) @ $0 · Other (J): 8,300 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Karydas Daphne — Director | Grant/award (A): 6,200 @ $0 · Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | DiRocco Derek — Director | Grant/award (A): 6,200 @ $0 · Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Levy Adam Scott — CFO and Secretary | Grant/award (A): 39,900 @ $0 · Grant/award (A): 53,300 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Rodman David Malcom — Chief Medical Officer | Grant/award (A): 38,400 @ $0 · Grant/award (A): 51,300 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Congleton Jon — Chief Executive Officer, Director | Grant/award (A): 140,900 @ $0 · Grant/award (A): 187,900 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director RA Capital Healthcare Fund LP — Director RA Capital Nexus Fund III, L.P. — Director Kolchinsky Peter — Director Shah Rajeev M. — Director | Grant/award (A): 6,200 @ $0 · Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | SBLENDORIO GLENN — Director | Grant/award (A): 6,200 @ $0 · Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | AKKARAJU SRINIVAS — Director, 10% owner | Grant/award (A): 6,200 @ $0 · Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 417 @ $15.44 · Sale (S): 417 @ $27.59 · Option exercise (M): 417 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 6,349 @ $1.08 · Sale (S): 5,828 @ $28.94 · Sale (S): 521 @ $29.64 · Option exercise (M): 3,541 @ $10.20 · Sale (S): 3,541 @ $27.33 · Option exercise (M): 4,166 @ $14.25 · +5 more | EDGAR |
| 2026-02-11 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 2,171 @ $16 · Sale (S): 2,171 @ $30.21 · Option exercise (M): 2,171 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 416 @ $15.44 · Sale (S): 416 @ $32.10 · Option exercise (M): 416 (derivative) @ $0 | EDGAR |
| 2026-01-15 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 3,542 @ $10.20 · Option exercise (M): 4,167 @ $14.25 · Sale (S): 7,709 @ $32.75 · Sale (S): 11,367 @ $32.61 · Option exercise (M): 3,542 (derivative) @ $0 · Option exercise (M): 4,167 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Levy Adam Scott — CFO and Secretary | Sale (S): 10,758 @ $32.14 | EDGAR |
| 2026-01-13 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 2,170 @ $16 · Sale (S): 2,170 @ $33.27 · Option exercise (M): 6,348 @ $1.08 · Sale (S): 6,348 @ $32.32 · Option exercise (M): 2,170 (derivative) @ $0 · Option exercise (M): 6,348 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Congleton Jon — Chief Executive Officer, Director | Sale (S): 9,119 @ $32.21 · Sale (S): 7,117 @ $33.15 | EDGAR |
| 2026-01-06 | 4 | Rodman David Malcom — Chief Medical Officer | Option exercise (M): 10,053 @ $1.08 · Option exercise (M): 3,629 @ $15.44 · Option exercise (M): 9,347 @ $10.20 · Option exercise (M): 20,168 @ $16 · Option exercise (M): 24,193 @ $14.25 · Sale (S): 70,037 @ $35.87 · +17 more | EDGAR |
| 2025-11-24 | 4 | Congleton Jon — Chief Executive Officer, Director | Option exercise (M): 24,082 @ $0.54 · Option exercise (M): 24,082 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Slingsby Brian Taylor — Director, 10% owner Catalys Pacific Fund, LP — 10% owner | Sale (S): 1,000,000 @ $43.35 | EDGAR |
| 2025-11-13 | 4 | Gold Alexander M — Director | Option exercise (M): 15,000 @ $10.20 · Sale (S): 10,000 @ $42.43 · Sale (S): 5,000 @ $47.08 · Option exercise (M): 6,933 @ $10.20 · Sale (S): 5,000 @ $46.50 · Sale (S): 1,933 @ $47.28 · +7 more | EDGAR |
| 2025-11-13 | 4 | Karydas Daphne — Director | Option exercise (M): 15,000 @ $10.20 · Sale (S): 10,115 @ $45.81 · Sale (S): 4,885 @ $46.36 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Levy Adam Scott — CFO and Secretary | Option exercise (M): 20,547 @ $10.20 · Option exercise (M): 34,414 @ $16 · Option exercise (M): 44,079 @ $14.25 · Option exercise (M): 6,613 @ $15.44 · Sale (S): 1,015 @ $42 · Sale (S): 11,295 @ $41.87 · +11 more | EDGAR |
| 2025-11-13 | 4 | Congleton Jon — Chief Executive Officer, Director | Sale (S): 12,806 @ $41.64 · Sale (S): 8,862 @ $42.31 · Sale (S): 4,000 @ $43.50 · Sale (S): 29,207 @ $45.20 · Sale (S): 112,275 @ $45.83 · Sale (S): 32,850 @ $46.89 | EDGAR |
| 2025-10-15 | 4 | Levy Adam Scott — CFO and Secretary | Sale (S): 7,366 @ $41.90 · Sale (S): 3,392 @ $42.26 | EDGAR |
Recent 8-K events — Mineralys Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2026-05-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-06 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MLYS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →